Movement Alert｜PHARMARON Rises 3.46% in Regular Trading, CXO Sector Rallies on Policy Tailwinds and Strong H1 Earnings

Market Focus09-29 09:54

On September 29, PHARMARON rose 3.46% in regular trading, trading at 31.16 HKD/share, with turnover of approximately 20.40 million HKD. The stock gained alongside a broad CXO sector rally driven by favorable policy developments and robust mid-year earnings.

On the policy front, the recently released pharmaceutical industry plan under the national 15th Five-Year framework has designated biopharma as a national emerging pillar industry, targeting annual growth of no less than 20% for the innovative drug sector, with AI-powered drug development highlighted as a key priority. The policy catalysts have continued to lift the CXO sector broadly, with peers WUXI BIO up 3.93%, WUXI APPTEC up 3.3%, and INSILICO up 4.0%.

Fundamentally, PHARMARON reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with adjusted net profit of RMB 909 million, up 20.3%. The company guided full-year revenue growth of 15% to 20%. Morgan Stanley recently maintained an Overweight rating with a target price of 35.6 HKD, implying meaningful upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188550256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188550256","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.46% in Regular Trading, CXO Sector Rallies on Policy Tailwinds and Strong H1 Earnings","media":"Market Focus","content":"<p><p>On September 29, PHARMARON rose 3.46% in regular trading, trading at 31.16 HKD/share, with turnover of approximately 20.40 million HKD. The stock gained alongside a broad CXO sector rally driven by favorable policy developments and robust mid-year earnings.</p><p>On the policy front, the recently released pharmaceutical industry plan under the national 15th Five-Year framework has designated biopharma as a national emerging pillar industry, targeting annual growth of no less than 20% for the innovative drug sector, with AI-powered drug development highlighted as a key priority. The policy catalysts have continued to lift the CXO sector broadly, with peers WUXI BIO up 3.93%, WUXI APPTEC up 3.3%, and INSILICO up 4.0%.</p><p>Fundamentally, PHARMARON reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with adjusted net profit of RMB 909 million, up 20.3%. The company guided full-year revenue growth of 15% to 20%. Morgan Stanley recently maintained an Overweight rating with a target price of 35.6 HKD, implying meaningful upside from current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.46% in Regular Trading, CXO Sector Rallies on Policy Tailwinds and Strong H1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.46% in Regular Trading, CXO Sector Rallies on Policy Tailwinds and Strong H1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-29 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 29, PHARMARON rose 3.46% in regular trading, trading at 31.16 HKD/share, with turnover of approximately 20.40 million HKD. The stock gained alongside a broad CXO sector rally driven by favorable policy developments and robust mid-year earnings.</p><p>On the policy front, the recently released pharmaceutical industry plan under the national 15th Five-Year framework has designated biopharma as a national emerging pillar industry, targeting annual growth of no less than 20% for the innovative drug sector, with AI-powered drug development highlighted as a key priority. The policy catalysts have continued to lift the CXO sector broadly, with peers WUXI BIO up 3.93%, WUXI APPTEC up 3.3%, and INSILICO up 4.0%.</p><p>Fundamentally, PHARMARON reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with adjusted net profit of RMB 909 million, up 20.3%. The company guided full-year revenue growth of 15% to 20%. Morgan Stanley recently maintained an Overweight rating with a target price of 35.6 HKD, implying meaningful upside from current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1188550256","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188550256","pubTimestamp":1790646868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 29, PHARMARON rose 3.46% in regular trading, trading at 31.16 HKD/share, with turnover of approximately 20.40 million HKD. The stock gained alongside a broad CXO sector rally driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨 3.46%，CXO 板块因政策利好和上半年强劲盈利而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On September 29, PHARMARON rose 3.46% in regular trading, trading at 31.16 HKD/share, with turnover of approximately 20.40 million HKD. The stock gained alongside a broad CXO sector rally driven by favorable policy developments and robust mid-year earnings.On the policy front, the recently released pharmaceutical industry plan under the national 15th Five-Year framework has designated biopharma as a national emerging pillar industry, targeting annual growth of no less than 20% for the innovative drug sector, with AI-powered drug development highlighted as a key priority. The policy catalysts have continued to lift the CXO sector broadly, with peers WUXI BIO up 3.93%, WUXI APPTEC up 3.3%, and INSILICO up 4.0%.Fundamentally, PHARMARON reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with adjusted net profit of RMB 909 million, up 20.3%. The company guided full-year revenue growth of 15% to 20%. Morgan Stanley recently maintained an Overweight rating with a target price of 35.6 HKD, implying meaningful upside from current levels.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188550256","isCrawlerRequest":true}